• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Journal of Andrology >Testosterone improves erectile function in hypogonadal patients with venous leakage.
【24h】

Testosterone improves erectile function in hypogonadal patients with venous leakage.

机译：睾丸激素可改善性腺功能减退患者的勃起功能。

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

The goal of this study was to assess the therapeutic benefits of long-acting testosterone therapy in hypogonadal patients with erectile dysfunction (ED). We recruited 29 patients with ED, ranging in age from 32 to 65 years (mean +/- SD, 47 +/- 9.7 years), with low plasma testosterone, who did not respond to phosphodiesterase type 5 inhibitor therapy. To evaluate penile arterial and venous blood flow, we employed duplex Doppler ultrasonography. For confirmation of diagnosis of venous leakage, pharmacocavernosography was carried out in 9 patients and magnetic resonance imaging with intracavernous contrast enhancement was carried out in 8 patients. All patients were treated with 1000 mg injectable testosterone undecanoate on day 1, followed by another injection after 6 weeks and every 3 months thereafter, in accordance with Nebido therapy protocol. Plasma testosterone levels were determined in all patients at baseline and after 18 and 30 weeks of testosterone treatment. The International Index of ErectileFunction (IIEF-5) was administered at baseline and after 18 and 30 weeks of testosterone treatment. At baseline total testosterone ranged from 7 to 11.8 nmol/L (200 to 345 ng/dL) in 25 patients. Eighteen and 30 weeks after testosterone treatment, the mean testosterone plasma levels were 18 and 21.5 nmol/L (520 and 625 ng/dL), respectively. After 18 and 30 weeks of testosterone treatment, 20 out of the 29 patients demonstrated marked improvement in erectile function domain, as assessed by the IIEF-5. This was also associated with diminution of venous leakage. We suggest that, in hypogonadal men with ED, testosterone therapy improves erectile function in patients with ED and venous leakage.
机译：这项研究的目的是评估长效睾丸激素治疗对勃起功能障碍（ED）的性腺功能减退患者的治疗效果。我们招募了29名ED患者，他们的年龄在32至65岁之间（平均+/- SD，47 +/- 9.7岁），血浆睾丸激素水平低，对5型磷酸二酯酶抑制剂治疗无反应。为了评估阴茎动脉和静脉的血流量，我们采用了双工多普勒超声检查。为确诊静脉渗漏，对9例患者进行了体腔海绵造影，对8例患者进行了腔内造影增强磁共振成像。根据Nebido治疗方案，所有患者在第1天均接受1000 mg癸酸睾丸激素注射液治疗，然后在6周后以及之后每3个月进行另一次注射。在基线时以及睾丸激素治疗18周和30周后，对所有患者的血浆睾丸激素水平进行了测定。国际勃起功能指数（IIEF-5）在基线以及睾丸激素治疗18和30周后给药。在基线时，25名患者的总睾酮范围为7至11.8 nmol / L（200至345 ng / dL）。睾丸激素治疗后18周和30周，平均睾丸激素水平分别为18和21.5 nmol / L（520和625 ng / dL）。根据IIEF-5评估，在接受睾丸激素治疗18周和30周后，在29名患者中有20名表现出勃起功能域的明显改善。这也与静脉渗漏减少有关。我们建议，对于患有ED的性腺功能低下的男性，睾丸激素疗法可改善ED和静脉渗漏患者的勃起功能。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号